What is the address of Medicorps-Invest?

The registered office of Medicorps-Invest is located at Boekenberglei 114, 2100 Antwerpen.

Is Medicorps-Invest still active?

Yes. According to the CBE (30 October 2026) Medicorps-Invest is active, legal situation “Normale toestand”, started on 5 November 2020.

Is Medicorps-Invest registered on Peppol?

No, Medicorps-Invest is currently not registered on the Peppol network.

What is the enterprise number of Medicorps-Invest?

The enterprise number of Medicorps-Invest is BE0757843479.

When was Medicorps-Invest founded?

Medicorps-Invest was founded on 5 November 2020.

Who are the directors of Medicorps-Invest?

According to the 2024 annual accounts, the directors of Medicorps-Invest are: Limasol BV, Edmond D'hont, Ficlasol BV, Ficaz BV.

Is Medicorps-Invest a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 5 November 2020; 3 annual accounts filed, latest fiscal year 2024; 4 directors known from the annual account.

How much profit did Medicorps-Invest make in 2024?

Medicorps-Invest recorded a loss after taxes of € 1,196 in financial year 2024.

What is the revenue of Medicorps-Invest?

As a small company, Medicorps-Invest is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € -780.

Does Medicorps-Invest have a website?

Yes, Medicorps-Invest has a website at skinline.be.

Medicorps-Invest (Private Limited) - Antwerpen

Dossier Medicorps-Invest, printed on 30 October 2026 from databakkes.be/en/0757843479/medicorps-invest. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2023 and 2024.
Tight liquidity NBB

Cash and receivables cover 51 % of short-term debt in 2024; threshold 65 %.
Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2024

Medicorps-Invest from Antwerpen, company number BE0757843479, closed financial year 2024 with a result of € -1,196 after tax. For that financial year Medicorps-Invest recorded a gross margin of € -780 and equity of € 23,415. Compared with financial year 2023, the result moved from € -389 to € -1,196. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on April 24, 2026.

What it is worth Healthy

€ 23,415

▼ 5% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -1,196

▼ 208 % more loss than in 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 1,815

▼ 23% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -1,585.

Debts at end 2024

Bank debt

None

No bank loans on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	Change 2023 → 2024
Gross margin	-	€ -389 Gross margin 2023: € -389 First fiscal year in the series	€ -780 Gross margin 2024: € -780 ▼ € 391 vs 2023 (€ -389) Unfavourable step	▼ € 391
Profit after taxes	€ 0 Profit after taxes 2022: € 0 First fiscal year in the series	€ -389 Profit after taxes 2023: € -389 Unchanged (€ 0) Unfavourable step	€ -1,196 Profit after taxes 2024: € -1,196 ▼ € 807 vs 2023 (€ -389) Unfavourable step	▼ € 807
Equity	€ 25,000 Equity 2022: € 25,000 First fiscal year in the series	€ 24,611 Equity 2023: € 24,611 ▼ 2% vs 2022 (€ 25,000) Unfavourable step	€ 23,415 Equity 2024: € 23,415 ▼ 5% vs 2023 (€ 24,611) Unfavourable step	▼ 5%
Total debts	€ 285,000 Total debts 2022: € 285,000 First fiscal year in the series	€ 431,689 Total debts 2023: € 431,689 ▲ 51% vs 2022 (€ 285,000) Unfavourable step	€ 532,300 Total debts 2024: € 532,300 ▲ 23% vs 2023 (€ 431,689) Unfavourable step	▲ 23%
Cash	€ 25,000 Cash 2022: € 25,000 First fiscal year in the series	€ 2,364 Cash 2023: € 2,364 ▼ 91% vs 2022 (€ 25,000) Unfavourable step	€ 1,815 Cash 2024: € 1,815 ▼ 23% vs 2023 (€ 2,364) Unfavourable step	▼ 23%
Retained profit	€ 0 Retained profit 2022: € 0 First fiscal year in the series	€ -389 Retained profit 2023: € -389 Unchanged (€ 0) Unfavourable step	€ -1,585 Retained profit 2024: € -1,585 ▼ € 1,196 vs 2023 (€ -389) Unfavourable step	▼ € 1,196
Balance sheet total	€ 310,000 Balance sheet total 2022: € 310,000 First fiscal year in the series	€ 456,300 Balance sheet total 2023: € 456,300 ▲ 47% vs 2022 (€ 310,000) Unchanged	€ 555,715 Balance sheet total 2024: € 555,715 ▲ 22% vs 2023 (€ 456,300) Unchanged	▲ 22%

Key figures of Medicorps-Invest, fiscal years 2022 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to Medicorps-Invest?

What happened at Medicorps-Invest in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Apr 24, 2026 New annual accounts for financial year 2023: loss of € 389. filed late Source: NBB ↗
Nov 5, 2020 New establishment in Antwerpen. KBO
Nov 5, 2020 Start of the company according to the CBE. KBO

In short

From € 0 profit in 2022 to € 1,196 loss in 2024.

Original PDFs at the National Bank ↗

Management

Baan-Chang 50%

The stake of Baan-Chang comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Medicorps-Invest

Behind Medicorps-Invest are Limasol BV, Edmond D'hont, Ficlasol BV and Ficaz BV. The shares are held by Baan-Chang (50%).

Directors

According to the 2024 annual accounts

Limasol BV

Director · represented by Steven Geyskens

Also active at: ENRAF-NONIUS BELUX

Edmond D'hont

Director

Ficlasol BV

Director · represented by Armand Gilissen

Also active at: SKINCENTERS ANTWERPEN, MEDI - INVEST, Zimmer Benelux, Skincenters Brussel, Skincenters Mechelen, Skincenters Malle, ENRAF-NONIUS BELUX

Ficaz BV

Director · represented by Matthias Stas

Also active at: SKINCENTERS ANTWERPEN, Zimmer Benelux, Skincenters Brussel, Skincenters Mechelen, Skincenters Malle, ENRAF-NONIUS BELUX

Shareholders

Baan-Chang

50%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Boekenberglei 114

2100 Antwerpen

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.

All companies at this address →

SKINCENTERS ANTWERPEN same network

€ 207,238 gross margin · 2024

Baan-Chang same network

€ 363,897 gross margin · 2025

Skincenters Brussel same network

€ 62,490 gross margin · 2024

Skincenters Mechelen same network

€ -6,686 gross margin · 2024

Skincenters Malle same network

€ 121,642 gross margin · 2024

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS skinline.be

About

Technologies

AOSCloudflare CDNJSComplianzElementorGSAPGoogle AnalyticsGoogle FontsGoogle Tag ManagerNginxPHPRank MathSwiperWPMLWordPressjQueryjQuery UIjsDelivrlazysizes

Hosting & Email

Email provider

Rackspace Email

Hosting

COMBELL-AS, BE

Website info

HTTPS Ja

Languages EN, FR, NL

Features

Ads Contact page

Security

✓ HTTPS

✓ SPF

✗ DMARC

Network

✓ IPv6

Details

Company number: 0757.843.479
VAT number: BE 0757.843.479
Registered office: Boekenberglei 114, 2100 Antwerpen
Names & denominations: Medicorps-Invest
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 5 November 2020
Peppol: Not registered
Contact: skinline.be +32491418786

View on CBE Public ↗ Annual accounts (NBB) ↗